Avenue Therapeutics (NASDAQ:ATXI) released its quarterly earnings data on Wednesday. The company reported ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.48) by $0.05, Bloomberg Earnings reports.
ATXI traded up $0.09 on Thursday, hitting $6.00. The company’s stock had a trading volume of 176 shares, compared to its average volume of 13,701. The stock’s 50 day simple moving average is $6.04. The stock has a market cap of $99.36 million, a price-to-earnings ratio of -2.86 and a beta of -0.41. Avenue Therapeutics has a 12 month low of $2.08 and a 12 month high of $7.98.
Several research analysts recently commented on the stock. ValuEngine raised shares of Avenue Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, April 25th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Avenue Therapeutics in a report on Tuesday, May 14th.
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.
See Also: Net Income
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.